A decision support tool to optimize your cancer pipeline portfolio. From research and development to Market.
Cancer Highlights™ is BioSeeker Group’s flagship decision support tool, for portfolio assessment and planning of cancer drug development. Cancer Highlights™ uses standardized criteria in a five pillar assessment to compare drug development strategies in oncology, making it easy to find and compare analysis not only within one single Cancer Focus Area but also between different areas.
This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.Learn More
This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design.Learn More
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market.Learn More
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer.Learn More
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications.Learn More
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning.Learn More
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.Learn More
This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.Learn More
This report will be an important part of creating and implementing a market development plan for any lymphoma therapeutic drug to ensure that the optimal market conditions exist by the time the product is commercialized.Learn More